Aileen Ebenig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aileen Ebenig has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Mühlebach
Division of Veterinary Medicine, Paul-Ehrlich-Institut, 63225, Langen, Germany
6 shared publications - Mona V. Lange
Division of Veterinary Medicine, Paul-Ehrlich-Institut
3 shared publications Alexandra Kupke
Institute for Virology, Philipps University, Marburg, Germany
2 shared publications- Barbara S. Schnierle
Department of Virology, Paul-Ehrlich-Institut, Langen, Germany
2 shared publications - Christine Goffinet
Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin
2 shared publications - Christoph Schürmann
Institute for Cardiovascular Physiology, Goethe-University, Frankfurt, Germany
2 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-11
Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19
Four COVID-19 vaccines were developed, tested, and authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We described a hamster model of COVID-19 utilizing Wuhan-1 strain SARS-CoV-2, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein (Alum+S). Such animals were vaccinated with the authorized vaccines or Alum+S, challenged, and examined. All vaccinated hamsters produced antibodies targeting S. Neutralizing antibodies (nAb) were induced only by authorized vaccines. While nAbs were present after one vaccination with AdV-vaccines, mRNA vaccines needed a boost immunization. Upon challenge, all authorized vaccines protected from severe disease. Less tissue damage and no live virus (one exception) were detectable in the lungs. In contrast, Alum+S immunized hamsters developed VAERD. Our data reveal the absence of induction of VAERD by early commercial vaccines in hamsters, while animals´ immune responses and protection seem to match the clinical vaccine efficacy.
- 17 March 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-11
Open AccessDifferential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19
Four COVID-19 vaccines were developed, tested, and authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We described a hamster model of COVID-19 utilizing Wuhan-1 strain SARS-CoV-2, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein (Alum+S). Such animals were vaccinated with the authorized vaccines or Alum+S, challenged, and examined. All vaccinated hamsters produced antibodies targeting S. Neutralizing antibodies (nAb) were induced only by authorized vaccines. While nAbs were present after one vaccination with AdV-vaccines, mRNA vaccines needed a boost immunization. Upon challenge, all authorized vaccines protected from severe disease. Less tissue damage and no live virus (one exception) were detectable in the lungs. In contrast, Alum+S immunized hamsters developed VAERD. Our data reveal the absence of induction of VAERD by early commercial vaccines in hamsters, while animals´ immune responses and protection seem to match the clinical vaccine efficacy.
- Open Access
- 30 May 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (23)
TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution
The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes remains unclear. To investigate this in more detail, we performed infection assays in engineered cells promoting ACE2-mediated entry with and without TMPRSS2 coexpression. Electron microscopy and inhibitor experiments indicated TMPRSS2-mediated cell entry was associated with increased virion internalization into endosomes, and partially dependent upon clathrin-mediated endocytosis. TMPRSS2 increased panvariant uptake efficiency and enhanced early rates of virus replication, transcription, and secretion, with variant-specific profiles observed. On the host side, transcriptional profiling confirmed the magnitude of infection-induced antiviral and proinflammatory responses were linked to uptake efficiency, with TMPRSS2-assisted entry boosting early antiviral responses. In addition, TMPRSS2-enhanced infections increased rates of cytopathology, apoptosis, and necrosis and modulated virus secretion kinetics in a variant-specific manner. On the virus side, convergent signatures of cell-uptake-dependent innate immune induction were recorded in viral genomes, manifesting as switches in dominant coupled Nsp3 residues whose frequencies were correlated to the magnitude of the cellular response to infection. Experimentally, we demonstrated that selected Nsp3 mutations conferred enhanced interferon antagonism. More broadly, we show that TMPRSS2 orthologues from evolutionarily diverse mammals facilitate panvariant enhancement of cell uptake. In summary, our study uncovers previously unreported associations, linking cell entry efficiency to innate immune activation kinetics, cell death rates, virus secretion dynamics, and convergent selection of viral mutations. These data expand our understanding of TMPRSS2’s role in the SARS-CoV-2 life cycle and confirm its broader significance in zoonotic reservoirs and animal models.
- 30 May 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (23)
Open AccessTMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution
The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes remains unclear. To investigate this in more detail, we performed infection assays in engineered cells promoting ACE2-mediated entry with and without TMPRSS2 coexpression. Electron microscopy and inhibitor experiments indicated TMPRSS2-mediated cell entry was associated with increased virion internalization into endosomes, and partially dependent upon clathrin-mediated endocytosis. TMPRSS2 increased panvariant uptake efficiency and enhanced early rates of virus replication, transcription, and secretion, with variant-specific profiles observed. On the host side, transcriptional profiling confirmed the magnitude of infection-induced antiviral and proinflammatory responses were linked to uptake efficiency, with TMPRSS2-assisted entry boosting early antiviral responses. In addition, TMPRSS2-enhanced infections increased rates of cytopathology, apoptosis, and necrosis and modulated virus secretion kinetics in a variant-specific manner. On the virus side, convergent signatures of cell-uptake-dependent innate immune induction were recorded in viral genomes, manifesting as switches in dominant coupled Nsp3 residues whose frequencies were correlated to the magnitude of the cellular response to infection. Experimentally, we demonstrated that selected Nsp3 mutations conferred enhanced interferon antagonism. More broadly, we show that TMPRSS2 orthologues from evolutionarily diverse mammals facilitate panvariant enhancement of cell uptake. In summary, our study uncovers previously unreported associations, linking cell entry efficiency to innate immune activation kinetics, cell death rates, virus secretion dynamics, and convergent selection of viral mutations. These data expand our understanding of TMPRSS2’s role in the SARS-CoV-2 life cycle and confirm its broader significance in zoonotic reservoirs and animal models.
- Open Access
- 24 April 2024
- Published by Springer Nature in Research Square
Hamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis
To combat the COVID-19 pandemic, vaccines have been developed, tested and approved in less than one year. Four vaccines using two technology platforms were authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We already described a hamster model of severe COVID-19, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein. Such animals were vaccinated here with the early authorized vaccines, challenged, and examined for immunopathogenesis in comparison to Alum+S-vaccinated or naïve hamster after challenge. All vaccinated hamsters produced antibodies binding (bAb) to SARS-CoV-2 Spike, while neutralizing antibodies (nAb) were induced only by the authorized vaccines. Among those, uniform induction of nAbs by mRNA vaccines needed a second dose. Using AdV-based vaccines, nAbs were mostly abundant after just one vaccination, but boostability was low. Upon challenge, Alum+S immunized animals were not protected and developed VAERD. In contrast, all authorized vaccines protected from severe disease, but transient initial weight loss was observed. In accordance with lower nAb titers, a tendency for higher weight loss became evident with Vaxzevria. Histopathology revealed less tissue damage after immunization with the authorized vaccines, with two animals revealing unaffected, healthy lungs. No live virus was detectable in lung tissue in those vaccine groups, except for one animal with Vaxzevria. Our data reveal absence of induction of VAERD by the authorized vaccines in a susceptible hamster model, while the induced immune responses and observed degree of protection seem to match the clinical vaccine efficacy.
- 24 April 2024
- Published by Springer Nature in Research Square
Open AccessHamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis
To combat the COVID-19 pandemic, vaccines have been developed, tested and approved in less than one year. Four vaccines using two technology platforms were authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We already described a hamster model of severe COVID-19, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein. Such animals were vaccinated here with the early authorized vaccines, challenged, and examined for immunopathogenesis in comparison to Alum+S-vaccinated or naïve hamster after challenge. All vaccinated hamsters produced antibodies binding (bAb) to SARS-CoV-2 Spike, while neutralizing antibodies (nAb) were induced only by the authorized vaccines. Among those, uniform induction of nAbs by mRNA vaccines needed a second dose. Using AdV-based vaccines, nAbs were mostly abundant after just one vaccination, but boostability was low. Upon challenge, Alum+S immunized animals were not protected and developed VAERD. In contrast, all authorized vaccines protected from severe disease, but transient initial weight loss was observed. In accordance with lower nAb titers, a tendency for higher weight loss became evident with Vaxzevria. Histopathology revealed less tissue damage after immunization with the authorized vaccines, with two animals revealing unaffected, healthy lungs. No live virus was detectable in lung tissue in those vaccine groups, except for one animal with Vaxzevria. Our data reveal absence of induction of VAERD by the authorized vaccines in a susceptible hamster model, while the induced immune responses and observed degree of protection seem to match the clinical vaccine efficacy.
- Open Access
- 3 April 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (5) , 860-874
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
- 3 April 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (5) , 860-874
Open AccessLive-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
- Open Access
- 15 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-12
Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
- 15 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-12
Open AccessVersatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
- Open Access
- 30 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (51) , 32657-32666
A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine
The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. Upon challenge using a mouse-adapted SARS-CoV-2, virus loads in vaccinated mice were significantly lower, while vaccinated Syrian hamsters revealed protection in a harsh challenge setup using an early-passage human patient isolate. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Significance The COVID-19 pandemic has already caused over 1 million deaths. Therefore, effective vaccine concepts are urgently needed. In search of such a concept, we have analyzed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well-known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity, yielding antiviral efficacy in vivo with the desired immune bias. Consequently, no immunopathologies became evident during challenge experiments. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.
- 30 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (51) , 32657-32666
Open AccessA highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine
The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. Upon challenge using a mouse-adapted SARS-CoV-2, virus loads in vaccinated mice were significantly lower, while vaccinated Syrian hamsters revealed protection in a harsh challenge setup using an early-passage human patient isolate. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Significance The COVID-19 pandemic has already caused over 1 million deaths. Therefore, effective vaccine concepts are urgently needed. In search of such a concept, we have analyzed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well-known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity, yielding antiviral efficacy in vivo with the desired immune bias. Consequently, no immunopathologies became evident during challenge experiments. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.
- 15 March 2016
- Published by Wiley in Angewandte Chemie
- Vol. 128 (16) , 5169-5173
Ein Apoptose‐induzierendes Heptamer, das effizient den Todesrezeptor 5 bündelt
Multivalente Liganden von Todesrezeptoren sind vielversprechende tumorspezifische Wirkstoffe, da sie eine apoptotische Kaskade in Krebszellen induzieren. Hier beschreiben wir einen modularen Ansatz für den Aufbau von Konstrukten, die an den Todesrezeptor 5 (“death receptor 5”, DR5) binden. In diesen Konstrukten sind mehrere Kopien gegen DR5 gerichteter Peptide (DR5TP) kovalent mit biomolekularen Gerüsten verknüpft. Mit dieser Strategie gelingt eine effiziente Oligomerisierung der Peptide in verschiedenen räumlichen Orientierungen durch enzymvermittelte Konjugationen oder rekombinante Produktion. Heptamere Konstrukte mit einem kurzen Gerüst (60–75 Reste) der C‐terminalen Oligomerisierungdomäne des humanen C4b‐Bindeproteins zeigten eine bemerkenswert hohe proapoptotische Aktivität (EC50=3 nm), wenn DR5TP an den Carboxyterminus ligiert wurde. Unsere Daten stützen die Ansicht, dass der Interligandabstand, die relative räumliche Orientierung und die Kopienzahl der rezeptorbindenden Module wesentliche Kriterien für die Rezeptoraktivierung und Zelltötung sind.
- 15 March 2016
- Published by Wiley in Angewandte Chemie
- Vol. 128 (16) , 5169-5173
Ein Apoptose‐induzierendes Heptamer, das effizient den Todesrezeptor 5 bündelt
Multivalente Liganden von Todesrezeptoren sind vielversprechende tumorspezifische Wirkstoffe, da sie eine apoptotische Kaskade in Krebszellen induzieren. Hier beschreiben wir einen modularen Ansatz für den Aufbau von Konstrukten, die an den Todesrezeptor 5 (“death receptor 5”, DR5) binden. In diesen Konstrukten sind mehrere Kopien gegen DR5 gerichteter Peptide (DR5TP) kovalent mit biomolekularen Gerüsten verknüpft. Mit dieser Strategie gelingt eine effiziente Oligomerisierung der Peptide in verschiedenen räumlichen Orientierungen durch enzymvermittelte Konjugationen oder rekombinante Produktion. Heptamere Konstrukte mit einem kurzen Gerüst (60–75 Reste) der C‐terminalen Oligomerisierungdomäne des humanen C4b‐Bindeproteins zeigten eine bemerkenswert hohe proapoptotische Aktivität (EC50=3 nm), wenn DR5TP an den Carboxyterminus ligiert wurde. Unsere Daten stützen die Ansicht, dass der Interligandabstand, die relative räumliche Orientierung und die Kopienzahl der rezeptorbindenden Module wesentliche Kriterien für die Rezeptoraktivierung und Zelltötung sind.